Literature DB >> 9869017

Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. Systolic Hypertension in China (Syst-China) Collaborative Group.

L Liu1, J G Wang, L Gong, G Liu, J A Staessen.   

Abstract

BACKGROUND: Isolated systolic hypertension occurs in around 8% of Chinese people aged 60 years or older. In 1988, the Systolic Hypertension in China (Syst-China) Collaborative Group started to investigate whether active treatment could reduce the incidence of stroke and other cardiovascular complications in older patients with isolated systolic hypertension.
METHODS: All patients were initially started on masked placebo. After stratification for centre, sex and previous cardiovascular complications, alternate patients (n=1253) were assigned nitrendipine at 10-40 mg daily, with the addition of captopril at 12.5-50.0 mg daily or hydrochlorothiazide at 12.5-50.0 mg daily, or both, if a sufficient blood pressure fall was not obtained. In the remaining 1141 control patients, matching placebos were administered similarly.
RESULTS: At entry, sitting blood pressure averaged 170.5 mmHg systolic and 86.0 mmHg diastolic, age averaged 66.5 years and total serum cholesterol was 5.1 mmol/l. After 2 years of follow-up, sitting systolic and diastolic blood pressures had fallen by 10.9 mmHg and 1.9 mmHg in the placebo group and by 20.0 mmHg and 5.0 mmHg in the active treatment group. The intergroup differences were 9.1 mmHg systolic (95% confidence interval 7.6-10.7 mmHg ) and 3.2 mmHg diastolic (95% confidence interval 2.4-4.0). Active treatment reduced total strokes by 38% (from 20.8 to 13.0 endpoints per 1000 patient-years, P=0.01), all-cause mortality by 39% (from 28.4 to 17.4 endpoints per 1000 patient-years, P=0.003), cardiovascular mortality by 39% (from 15.2 to 9.4 endpoints per 1000 patient-years, P=0.03), stroke mortality by 58% (from 6.9 to 2.9 endpoints per 1000 patient-years, P=0.02), and ail fatal and nonfatal cardiovascular endpoints by 37% (from 33.3 to 21.4 endpoints per 1000 patient-years, P=0.004).
CONCLUSIONS: Antihypertensive treatment prevents stroke and other cardiovascular complications in older Chinese patients with isolated systolic hypertension. Treatment of 1000 Chinese patients for 5 years could prevent 55 deaths, 39 strokes or 59 major cardiovascular endpoints.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9869017     DOI: 10.1097/00004872-199816120-00016

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  128 in total

Review 1.  Recent advances in the management of hypertension in the elderly.

Authors:  F J Gennari; A S Gennari
Journal:  Curr Hypertens Rep       Date:  2000-12       Impact factor: 5.369

Review 2.  Pharmacoeconomics of hypertension management: the place of combination therapy.

Authors:  E Ambrosioni
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

3.  Current trials.

Authors:  F H Messerli
Journal:  Curr Hypertens Rep       Date:  1999-06       Impact factor: 5.369

Review 4.  The elderly patients on hemodialysis.

Authors:  S Anand; M Kurella Tamura; G M Chertow
Journal:  Minerva Urol Nefrol       Date:  2010-03       Impact factor: 3.720

Review 5.  Evidence for aggressive blood pressure-lowering goals in patients with coronary artery disease.

Authors:  Monisankar Roy; Noman Mahmood; Clive Rosendorff
Journal:  Curr Atheroscler Rep       Date:  2010-03       Impact factor: 5.113

Review 6.  Pulsatile and Steady-State Pressure Trends in Children: Is the Future Now?: Comment on the Paper by Zachariah and Kovacikova [Pulse 2014;2:57-62].

Authors:  Michael F O'Rourke
Journal:  Pulse (Basel)       Date:  2015-02-03

Review 7.  Antihypertensive therapy in the prevention of stroke: what, when and for whom?

Authors:  M D Fotherby; B Panayiotou
Journal:  Drugs       Date:  1999-10       Impact factor: 9.546

8.  Closing remarks: current position of calcium channel antagonists in hypertension--the role of manidipine.

Authors:  Alberto Zanchetti
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 9.  Hypertension in the elderly.

Authors:  M Pestana
Journal:  Int Urol Nephrol       Date:  2001       Impact factor: 2.370

Review 10.  Current treatment of patients with hypertension: therapeutic implications of INSIGHT.

Authors:  Stefano Taddei; Lorenzo Ghiadoni; Antonio Salvetti
Journal:  Drugs       Date:  2003       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.